ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Courts Find Gilead "Morally Blameworthy" for Withholding HIV Medication

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
California's Court of Appeals denies Gilead Sciences' request for immunity from liability

BALTIMORE, MD, January 23, 2024 /24-7PressRelease/ -- In a pivotal decision, the California Court of Appeal rejected Gilead Sciences' bid for immunity from liability in a case involving its HIV medications. This ruling represents a critical juncture in the ongoing legal dispute over Gilead's management of its HIV antiretroviral drugs, particularly the delayed release of tenofovir alafenamide (TAF), a safer alternative to its existing medication, tenofovir disoproxil fumarate (TDF).

The Court's comprehensive 62-page opinion firmly denounces Gilead's approach, highlighting the company's alleged strategy to maximize profits from TDF at the expense of patient safety. The California Court of Appeal's decision clarifies that Gilead had a legal duty to avoid foreseeable harm to the users of its medications, rebuking the pharmaceutical giant's rejection of that obligation.

The case, which involves more than 22,000+ lawsuits consolidated in a mass tort action, accuses Gilead of intentionally delaying the development of TAF despite being aware of its safer profile compared to TDF. The extensive discovery phase of the litigation revealed internal documents suggesting Gilead could have released TAF significantly earlier than its eventual 2015 U.S. Food and Drug Administration (FDA) approval, thereby preventing harm to patients. The prolonged exposure to TDF significantly increased the risks to kidney and bone health.

The Court found Gilead's actions "morally blameworthy," emphasizing the ethical implications of their decision-making process.

Co-lead counsel Robert K. Jenner of Jenner Law has been instrumental in bringing these allegations to light. He has reaffirmed its commitment to seeking justice for those adversely affected by TDF, emphasizing the importance of holding corporations accountable for their actions.

About Jenner Law

Jenner Law is a nationally recognized personal injury law firm renowned for its commitment to representing individuals in life-altering injury cases. With offices in Maryland, Virginia, and Massachusetts, the firm specializes in complex cases involving dangerous drugs and medical devices, sexual abuse, and general negligence.

Led by Robert K. Jenner, one of "America's 55 Most Influential Trial Lawyers," the firm has established itself at the forefront of significant legal battles, including the high-profile case against Gilead Sciences over its HIV medication.

The Jenner Law team includes accomplished attorneys Katie Kerner and Elisha Hawk and offers expertise in a range of areas, from sexual abuse lawsuits, including clergy and therapist abuse, to personal injury cases involving catastrophic injuries and environmental pollutants.

---
Press release service and press release distribution provided by https://www.24-7pressrelease.com
Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  255.08
-0.28 (-0.11%)
AAPL  273.43
+0.26 (0.10%)
AMD  305.33
+1.87 (0.62%)
BAC  52.47
-0.65 (-1.22%)
GOOG  337.75
+0.02 (0.01%)
META  659.15
-15.57 (-2.31%)
MSFT  415.75
-17.17 (-3.97%)
NVDA  199.64
-2.86 (-1.41%)
ORCL  176.28
-11.22 (-5.98%)
TSLA  373.72
-13.79 (-3.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.